menu
    • menu

    Company profile for Suanfarma

    Suanfarma-PSE
    News
    Leading the Way in Tetracycline APIs

    21 Nov 2024

    // PRESS RELEASE

    Fluralaner:Most Effective Treatment Mite Infestations In Chickens

    25 Sep 2024

    // PRESS RELEASE

    Boosting Livestock Health with Tiamulin, a Reliable Solution for Animal Health

    22 Aug 2024

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Suanfarma

    Contact Supplier

    Website

    CPhI North America

    Booth #1219

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/9IzvFN6AABg

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Suanfarma, at the Core of a Better Life.

    Related CompaniesRelated Companies

    About

    Suanfarma founded in 1993, is a B2B life science partner committed to health advancement by developing, manufacturing, & distributing high-quality APIs for the pharmaceutical industry innovatively & sustainably. Backed by a robust global network of 12 strategically located local offices, we cater to the needs of over 400 active customers in 70+ countries. At Suanfarma we offer our CDMO capacity for fermentation & chemical synthesis projects, offering a One Stop Shop service with a solid track record, & which allows us to achieve success in the development, scaling, manufacturing, & commercialization of an API, either innovative or generic.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SuanfarmaSpain_new Flag
    Country
    Country
    Spain
    Address
    Address
    Einstein, 8- 28108 Alcobendas, Madrid
    Telephone
    Telephone
    +34 913446890
    Client Email
    Email
    info@suanfarma.com
    Client Website
    Website
    https://www.suanfarma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/suanfarma-s.a.
    youtube
    YouTube
    https://www.youtube.com/@suanfarma
    Twitter
    Twitter
    https://x.com/suanfarma?lang=en
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    A PHP Error was encountered

    Severity: Warning

    Message: Undefined variable $tile1

    Filename: tabs/exhibitions.php

    Line Number: 43

    Backtrace:

    File: /var/www/html/application/views/include/party/inc/tabs/exhibitions.php
    Line: 43
    Function: _error_handler

    File: /var/www/html/application/models/CmnPec.php
    Line: 1631
    Function: view

    File: /var/www/html/application/views/include/party/query.php
    Line: 605
    Function: create

    File: /var/www/html/application/views/include/party/indexNew.php
    Line: 70
    Function: include

    File: /var/www/html/application/views/commonNew.php
    Line: 445
    Function: include

    File: /var/www/html/application/controllers/PharmaServices.php
    Line: 4655
    Function: view

    File: /var/www/html/index.php
    Line: 224
    Function: require_once

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Booth #1219

    envelop Contact Supplier

    CPhI North America

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/suanfarma-party-content-95663.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Canagliflozin Hemihydrate: Transforming Type 2 Diabetes Care

    read-more

      https://www.pharmacompass.com/pdf/party/content/suanfarma-party-content-50404.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Strategic Rebranding Initiative under Suanfarma CDMO

    read-more

      https://www.pharmacompass.com/pdf/party/content/suanfarma-party-content-42582.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Human API Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/suanfarma-party-content-39956.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Veterinary API Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/suanfarma-party-content-78435.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Intermediates Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/suanfarma-party-content-94880.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Strategic Cooperation for Anti-infective & Antibacterial APIs

    read-more

      https://www.pharmacompass.com/pdf/party/content/suanfarma-party-content-94013.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Large Volume Anti-infective APIs Through Precision Fermentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/suanfarma-party-content-51363.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2900

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions

    #PharmaFlow by PHARMACOMPASS
    19 Dec 2024
    Share Share
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 13293

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Leading the Way in Tetracycline APIs
    Leading the Way in Tetracycline APIs

    21 Nov 2024

    // PRESS RELEASE

    https://www.suanfarma.com/apis-3/leading-the-way-in-tetracycline-apis/

    PRESS RELEASE
    21 Nov 2024
    Share Share
    Fluralaner:Most Effective Treatment Mite Infestations In Chickens
    Fluralaner:Most Effective Treatment Mite Infestations In Chickens

    25 Sep 2024

    // PRESS RELEASE

    https://www.suanfarma.com/veterinary/fluralaner-the-most-effective-treatment-against-mite-infestations-in-chickens/

    PRESS RELEASE
    25 Sep 2024
    Share Share
    Boosting Livestock Health with Tiamulin, a Reliable Solution for Animal Health
    Boosting Livestock Health with Tiamulin, a Reliable Solution for Animal Health

    22 Aug 2024

    // PRESS RELEASE

    https://www.suanfarma.com/uncategorized/boosting-livestock-health-with-tiamulin-a-reliable-solution-for-animal-health/

    PRESS RELEASE
    22 Aug 2024
    Share Share
    Data Integrity in the Pharmaceutical Industry
    Data Integrity in the Pharmaceutical Industry

    25 Jun 2024

    // PRESS RELEASE

    https://www.suanfarma.com/quality/data-integrity-in-the-pharmaceutical-industry/

    PRESS RELEASE
    25 Jun 2024
    Share Share
    The Challenges of a Multipurpose Plant in the Pharmaceutical Industry
    The Challenges of a Multipurpose Plant in the Pharmaceutical Industry

    18 Jun 2024

    // PRESS RELEASE

    https://www.suanfarma.com/cdmo/the-challenges-of-a-multipurpose-plant-in-the-pharmaceutical-industry/

    PRESS RELEASE
    18 Jun 2024
    Share Share
    Quality API Production through Fermentation and Chemical Synthesis
    Quality API Production through Fermentation and Chemical Synthesis

    03 Jun 2024

    // PRESS RELEASE

    https://www.suanfarma.com/quality/quality-api-production-through-fermentation-and-chemical-synthesis/

    PRESS RELEASE
    03 Jun 2024
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Suanfarma full-view

    TOP RANKED SUPPLIER FOR:

    Microbial Fermentation
    full-view
    Clinical Phases to Recurrent Production
    full-view
    Small Molecule API Contract Manufacturing
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    FDA

    read-more
    read-more

    01

    FDA Audited

    USA
    arrow
    CPhI North America
    Booth #1219

    District Decision : No Action Indicated

    Inspection End Date : 2021-05-19

    Suanfarma

    City : Fair Lawn

    State : NJ

    Country/Area : US

    Zip : 07410-2018

    District : NWJ

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2021-05-19

    Suanfarma

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    FDA Audited

    USA
    arrow
    CPhI North America
    Booth #1219

    District Decision : No Action Indicated

    Inspection End Date : 2019-06-19

    Suanfarma

    City : Fair Lawn

    State : NJ

    Country/Area : US

    Zip : 07410-2018

    District : NWJ

    Center : CFSAN

    Project Area : Foodborne Biological Hazards

    District Decision : No Action Indicated

    Inspection End Date : 2019-06-19

    Suanfarma

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    03

    FDA Audited

    USA
    arrow
    CPhI North America
    Booth #1219

    District Decision : No Action Indicated

    Inspection End Date : 2019-06-19

    Suanfarma

    City : Fair Lawn

    State : NJ

    Country/Area : US

    Zip : 07410-2018

    District : NWJ

    Center : CFSAN

    Project Area : Food Composition, Standards, Lab...

    District Decision : No Action Indicated

    Inspection End Date : 2019-06-19

    Suanfarma

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    04

    FDA Audited

    USA
    arrow
    CPhI North America
    Booth #1219

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2019-05-09

    Suanfarma

    City : Rovereto

    State :

    Country/Area : IT

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2019-05-09

    Suanfarma

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    05

    FDA Audited

    USA
    arrow
    CPhI North America
    Booth #1219

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2016-09-01

    Suanfarma

    City : Fair Lawn

    State : NJ

    Country/Area : US

    Zip : 07410-2018

    District : NWJ

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2016-09-01

    Suanfarma

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    06

    FDA Audited

    USA
    arrow
    CPhI North America
    Booth #1219

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2016-09-01

    Suanfarma

    City : Fair Lawn

    State : NJ

    Country/Area : US

    Zip : 07410-2018

    District : NWJ

    Center : CFSAN

    Project Area : Food Composition, Standards, Lab...

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2016-09-01

    Suanfarma

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    07

    FDA Audited

    USA
    arrow
    CPhI North America
    Booth #1219

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2015-02-06

    Suanfarma

    City : Rovereto

    State :

    Country/Area : IT

    Zip :

    District : ORA

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2015-02-06

    Suanfarma

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    08

    FDA Audited

    USA
    arrow
    CPhI North America
    Booth #1219

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2015-02-06

    Suanfarma

    City : Rovereto

    State :

    Country/Area : IT

    Zip :

    District : ORA

    Center : CVM

    Project Area : Monitoring of Marketed Animal Dr...

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2015-02-06

    Suanfarma

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    09

    FDA Audited

    USA
    arrow
    CPhI North America
    Booth #1219

    District Decision : No Action Indicated

    Inspection End Date : 2014-01-23

    Suanfarma

    City : Fair Lawn

    State : NJ

    Country/Area : US

    Zip : 07410-2018

    District : NWJ

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2014-01-23

    Suanfarma

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    10

    FDA Audited

    USA
    arrow
    CPhI North America
    Booth #1219

    District Decision : No Action Indicated

    Inspection End Date : 2014-01-23

    Suanfarma

    City : Fair Lawn

    State : NJ

    Country/Area : US

    Zip : 07410-2018

    District : NWJ

    Center : CFSAN

    Project Area : Food Composition, Standards, Lab...

    District Decision : No Action Indicated

    Inspection End Date : 2014-01-23

    Suanfarma

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Contact Suanfarma and get a quotation

    Suanfarma is a supplier offers 18 products (APIs, Excipients or Intermediates).

    Find a price of Minocycline Hydrochloride bulk with DMF, CEP, JDMF offered by Suanfarma

    Find a price of Tetracycline Hydrochloride bulk with DMF, CEP offered by Suanfarma

    Find a price of Lymecycline bulk with CEP offered by Suanfarma

    Find a price of Oxytetracycline Calcium bulk with DMF offered by Suanfarma

    Find a price of Oxytetracycline Hydrochloride bulk with DMF offered by Suanfarma

    Find a price of Tetracycline bulk with DMF offered by Suanfarma

    Find a price of Tiamulin Fumarate bulk with CEP offered by Suanfarma

    Find a price of Anastrozole bulk offered by Suanfarma

    Find a price of Bisoprolol Fumarate bulk offered by Suanfarma

    Find a price of Canagliflozin bulk offered by Suanfarma

    Find a price of Clomiphene Citrate bulk offered by Suanfarma

    Find a price of Fluralaner bulk offered by Suanfarma

    Find a price of Levosimendan bulk offered by Suanfarma

    Find a price of Opicapone bulk offered by Suanfarma

    Find a price of Oxytetracycline Dihydrate bulk offered by Suanfarma

    Find a price of Ribociclib bulk offered by Suanfarma

    Find a price of Rivaroxaban bulk offered by Suanfarma

    Find a price of Trimebutine Maleate bulk offered by Suanfarma

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search